Literature DB >> 2573533

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.

T M Engber1, Z Susel, J L Juncos, T N Chase.   

Abstract

The effects of continuous and intermittent levodopa treatment on rotational behavior induced by dopamine agonists were examined in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal dopamine pathway. Chronic administration of levodopa by continuous infusion (90-100 mg/kg per day i.p. by osmotic pump for 19 days with a 3 day washout) enhanced the rotational response to the D-2 dopamine receptor agonist quinpirole, but had no effect on rotation induced by the D-1 agonist SKF 38393 or that due to the non-selective dopamine agonist apomorphine. The rotational responses to the selective dopamine agonists differed dramatically in rats treated with levodopa by intermittent injection (45-50 mg/kg i.p., b.i.d. for 19 days with a 3 day washout): they showed a markedly increased response to quinpirole, a greatly diminished response to SKF 38393, and a modestly enhanced response to apomorphine. Continuous and intermittent treatment resulted in equivalent daily plasma levodopa levels. These findings suggest that the intermittence of central dopamine receptor stimulation may be an important factor in determining the subsequent responses of the dopamine system. The dissociation between the effects of both continuous and intermittent levodopa on D-1 and D-2 agonist-induced rotation indicates that D-1 and D-2 dopamine receptor-mediated mechanisms respond differently to chronic levodopa treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573533     DOI: 10.1016/0014-2999(89)90790-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Soluble and controlled-release preparations of levodopa: do we really need them?

Authors:  Giovanni Fabbrini; Flavio Di Stasio; Maria Bloise; Alfredo Berardelli
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

2.  Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  Masahiro Nomoto; Yoshikuni Mizuno; Tomoyoshi Kondo; Kazuko Hasegawa; Miho Murata; Masahiro Takeuchi; Junji Ikeda; Takayuki Tomida; Nobutaka Hattori
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

3.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

4.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

5.  Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.

Authors:  D M Yurek; K Steece-Collier; T J Collier; J R Sladek
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

Review 6.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

7.  L-dopa infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine.

Authors:  D E Dluzen; F T Kratko
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.

Authors:  T D L Steeves; J Miyasaki; M Zurowski; A E Lang; G Pellecchia; T Van Eimeren; P Rusjan; S Houle; A P Strafella
Journal:  Brain       Date:  2009-04-03       Impact factor: 13.501

9.  The dopamine D3 receptor and drug addiction.

Authors:  P Sokoloff; B Le Foll; S Perachon; R Bordet; S Ridray; J C Schwartz
Journal:  Neurotox Res       Date:  2001-10       Impact factor: 3.911

10.  The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats.

Authors:  D E Dluzen; B Liu
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.